| Aug 12 |
Lisata Therapeutics GAAP EPS of -$0.61 beats by $0.14
|
| Aug 12 |
Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 5 |
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
|
| Jul 24 |
Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal
|
| Jul 19 |
Lisata to use Haystack’s MRD tests for pancreatic cancer therapy trial
|
| Jul 18 |
Lisata to use Haystack technology to evaluate pancreatic cancer asset certepetide
|
| Jul 18 |
Haystack Oncology, Lisata Therapeutics Collaborate on Pancreatic Cancer Therapy
|
| Jul 18 |
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
|
| Jul 18 |
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
|
| Jul 16 |
Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why
|
